NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046)^[1][2]. NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo^[2].

NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100^[1].
NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors^[1].
NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells^[1].
NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

395.54

C₂₃H₃₃N₅O

1060524-97-1

Room temperature in continental US; may vary elsewhere.

• [1]. Mishra RK, et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.Sci Rep. 2016 Jul 26;6:30155.  [Content Brief]

  [2]. Negro S, et al. An?Agonist?of the?CXCR4?Receptor?Strongly?Promotes?Regeneration?of?Degenerated?Motor?Axon?Terminals.Cells.?2019 Sep 30;8(10). pii: E1183.  [Content Brief]